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The posttranslational methylation of N-terminal a-amino groups (a-N-methylation) is a ubiquitous
reaction found in all domains of life. Although this modiﬁcation usually occurs on protein sub-
strates, recent studies have shown that it also takes place on ribosomally synthesized natural prod-
ucts. Here we report an investigation of the bacterial a-N-methyltransferase CypM involved in the
biosynthesis of the peptide antibiotic cypemycin. We demonstrate that CypM has low substrate
selectivity and methylates a variety of oligopeptides, cyclic peptides such as nisin and haloduracin,
and the e-amino group of lysine. Hence it may have potential for enzyme engineering and combina-
torial biosynthesis. Bayesian phylogenetic inference of bacterial a-N-methyltransferases suggests
that they have not evolved as a speciﬁc group based on the chemical transformations they catalyze,
but that they have been acquired from various other methyltransferase classes during evolution.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction PrmA, a versatile enzyme that methylates not only the N-terminalPosttranslational methylation of N-terminal a-amino groups
(a-N-methylation) is a ubiquitous reaction found in both bacteria
and eukarya [1–10]. These reactions occur usually on protein sub-
strates that function as part of macromolecular complexes, includ-
ing the ribosome, chromatin, respiratory chains, photosynthetic
complexes, myoﬁbrils and bacterial pili [4]. Although the exact role
and the enzymology of a-N-methylation remains largely unknown,
recent studies have revealed that the N-terminal methylation of
Ran guanine nucleotide exchange factor RCC1 catalyzed by NRMT
(N-terminal RCC1 methyltransferase) is critical for normal bipolar
spindle formation and chromosome segregation in the mitotic
phase of mammalian cells [7,8]. NRMT was shown to be promiscu-
ous and is able to methylate protein substrates other than RCC1,
such as SET (also known as TAF-I or PHAPII) and the retinoblas-
toma protein RB [8]. An ortholog of NRMT in Drosophila melanogas-
ter, dNTMT, was shown to catalyze methylation of histone H2B
[10]. For bacteria, methylation of the ribosomal protein L11 has
been relatively well characterized. This reaction is catalyzed bychemical Societies. Published by E
obutyrine; Avi-Cys, S-[(Z)-2-
H, S-adenosylhomocysteine;
Markov chain Monte Carlo;
formamide; NMM, N-methyl
ionization; Abu, 2-aminobu-
Donk).a-amino group but also the e-amino group of Lys residues [11,12].
In addition to protein substrates, ribosomally synthesized pep-
tides also serve as substrates for a-N-methylation. The recently-
characterized thiazole/oxazole-modiﬁed peptide plantazolicin, for
example, contains an N,N-dimethylarginine residue that results
from a-N-methylation (Fig. 1) [13–15]. The N,N-dimethylalanine
(Me2-Ala) residue in cypemycin and its structural variant grisemy-
cin also results from a-N-methylation [16,17] (Fig. 1). Cypemycin
is a posttranslationally modiﬁed peptide antibiotic produced by
Streptomyces sp. OH-4156 with potent in vitro activity against
mouse leukemia cells [18]. Historically, it has been grouped in
the lantibiotic family because of its dehydrobutyrine (Dhb) resi-
dues and (Z)-2-aminovinyl-cysteine (Avi-Cys) moiety (Fig. 1),
which are also found in some lantibiotics [19,20]. However, cype-
mycin does not contain lanthionine or methyllanthionine rings,
and the Dhb and Avi-Cys residues are proposed to be introduced
by a pathway distinct from that of lantibiotic biosynthesis [16].
CypM, an enzyme of the methyltransferase 11 family, is responsi-
ble for the synthesis of the N-terminal Me2-Ala residue, as deletion
of cypM from the cypemycin biosynthetic gene cluster resulted in a
demethylated cypemycin derivative, which could be methylated
by CypM in vitro to produce cypemycin (Fig. 1) [16]. Interestingly,
the antimicrobial activity of demethylated cypemycin was almost
completely abolished. A similar result was found for plantazolicin,
as desmethylplantazolicin was devoid of activity against Bacillus
anthracis whereas plantazolicin displayed potent activity [15].
These results demonstrated a new role of a-N-methylation in the
biological activity of natural products.lsevier B.V. All rights reserved.
Fig. 1. N-Methylation of desmethyl cypemycin and plantazolicin catalyzed by CypM and PznL, respectively. The amino groups on which methylation occurs are highlighted
by dashed boxes. Dhb, dehydrobutyrine; a-Ile, allo-isoleucine; Avi-Cys, S-[(Z)-2-aminovinyl]-cysteine; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine. A
shorthand notation for these structures is shown below each chemical structure in the red box. The absolute conﬁguration of allo-Ile and Avi-Cys is not known.
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activity as well as the catalytic versatility found for NRMT and
PrmA, a-N-methyltransferases might possibly serve as a useful tool
for structural diversiﬁcation and functional optimization of peptide
antibiotics. Modiﬁcation of the N-terminus is an often-used strat-
egy for synthetic peptides to decrease the susceptibility to amino-
peptidases. Here we probed the catalytic speciﬁcities of CypM
using various synthetic and natural peptides. Our data show that
CypM has low substrate speciﬁcity and can methylate a series of
structurally distinct substrates, suggesting that catalytic promiscu-
ity might be a common property among a-N-methyltransferases
and demonstrating a potentially useful tool for future combinato-
rial biosynthesis studies. Phylogenetic analysis using the Bayesian
Markov chain Monte Carlo (MCMC) method [21] indicates that
bacterial a-N-methyltransferase may not have evolved from a
common ancestor, but were likely acquired several times from
other ancient methyltransferases.
2. Materials and methods
2.1. Chemicals, biochemicals, plasmids and strains
This information is provided in the Supplementary data.
2.2. Synthesis of oligopeptides
Peptides were synthesized using standard ﬂuorenylmethyloxy-
carbonyl (Fmoc) based solid phase peptide synthesis (SPPS) tech-
niques using a Rainin PS3 peptide synthesizer. Preloaded resin
(either Wang or 2-chlorotrityl; 0.1 mmol) was ﬁrst swollen in
dimethylformamide (DMF) (3  5 mL  10 min). Fmoc-amino
acids (0.4 mmol, 4 equiv) were coupled using O-(1H-6-chloro-
benzotriazol-1-yl)-N,N,N0,N0-tetramethyluronium hexaﬂuorophos-
phate (HCTU, 165 mg, 0.4 mmol, 4 equiv) as coupling reagent and
0.4 M N-methyl morpholine (NMM) as activating reagent
(45 min). Fmoc deprotection was performed with piperidine
(3  5 mL  3 min; 20% in DMF). After completion of the couplingof the ﬁnal amino acid, the Fmoc group was removed to generate
the free amino group.
Peptides were cleaved from the resin by adding a solution of tri-
ﬂuoroacetic acid (TFA) (5 mL), triisopropylsilane (TIPS) (100 lL),
and H2O (100 lL) to the resin (0.1 mmol), and stirring the solution
for 2 h at room temperature. The solution was concentrated by
purging with a nitrogen stream and peptides were precipitated
with cold diethyl ether. The crude peptides were dissolved in
0.1% aqueous TFA, lyophilized, and puriﬁed by preparative RP-
HPLC on a Waters Delta-PakTM C18 column (2.5 cm  10.0 cm)
employing a water-acetonitrile solvent system. HPLC fractions
containing products as conﬁrmed by (MALDI) mass spectrometry
(MS) were collected and lyophilized.
2.3. In vitro CypM assays
Detailed procedures for overexpression and puriﬁcation of
C-terminally hexa His-tagged CypM are described in the
Supplementary data. For in vitro methylation assays, peptide
substrates (100 lM) were incubated with CypM-His6 (20 lM) in
a reaction buffer containing 50 mM HEPES (pH 7.2), 0.5 mM
S-adenosylmethionine (SAM), 1 mM DTT, 100 mM NaCl and 0.01
U of S-adenosylhomocysteine hydrolase (from rabbit erythrocytes,
Sigma–Aldrich). The reactions were incubated at 37 C for 5 h.
Reactions were quenched by 5% TFA and the protein precipitate
was removed by centrifugation. Samples were analyzed directly
by liquid chromatography electrospray ionization tandem mass
spectrometry (LC/ESI–MS/MS) as described in the Supplementary
data. For MALDI-TOF MS analysis, samples were either puriﬁed
by reverse phase (C4) solid phase extraction or desalted using
ZipTipC18 before analysis.
2.4. Phylogenetic analysis
The protein sequences in this study were obtained from the
GenBank database; their accession numbers and the source organ-
isms are listed in Supplementary Table S1. The sequences were
Table 1
Methylation of short oligopeptides by CypM.
Peptide Sequence Observed methylation
1 AAPAAPA Mono-, Di-
2 AAPAAPS Di-
3 ASPAAPA Di-
4 ATPAAPA Mono-, Di-
5 ATPATPA Mono-, Di-
6 GAPAAPA Di-
7 SAPAAPA Di-
8 MAPAAPA Di-
9 KAPAAPA No reaction
10 AKPAAPA No reaction
11 AAPAAPK Di-, Tetra-
12 AAAATPT No reaction
13 APKAAPA No reaction
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each alignment step, and the alignments were manually ﬁne-tuned
afterwards. Bayesian inference was used to calculate posterior
probability of clades utilizing the program MrBayes (version 3.1)
[23]. Final analyses consisted of two sets of eight chains each
(one cold and seven heated), run for about 3 million generationsFig. 2. (A) Structure of nisin and its methylated derivatives. The amino groups on which
Dha, dehydroalanine; Dhb, dehydrobutyrine. For lanthionine and methyllanthionine stru
in blue. A shorthand notation for these structures used in the natural product drawings is
modiﬁed by CypM.with trees saved and parameters sampled every 100 generations.
Analyses were run to reach a convergence with standard deviation
of split frequencies <0.005. Posterior probabilities were averaged
over the ﬁnal 75% of trees (25% burn in). The analysis utilized a
mixed amino acid model with a proportion of sites designated
invariant, and rate variation among sites modeled after a gamma
distribution divided into eight categories, with all variable param-
eters estimated by the program based on BioNJ starting trees. The
ﬁgures of the Bayesian phylograms were prepared by using Tree-
View [24].
3. Results and discussion
3.1. CypM-catalyzed methylation of short oligopeptides
Cypemycin biosynthesis follows a common paradigm of ribo-
somal natural product maturation, involving posttranslational
modiﬁcations of the C-terminal core region of a precursor peptide
and subsequent proteolytic removal of an N-terminal leader se-
quence [25]. CypMmethylates the a-amino group of an N-terminal
Ala residue that is released by removal of the leader peptide. Be-
cause the leader peptide is typically indispensable for precursormethylation occurred are highlighted by dashed boxes. Abu, 2-aminobutyric acid;
ctures, the segments derived from Ser/Thr are in red and those derived from Cys are
shown below each chemical structure. (B) MS spectra of nisin A and nisin A in vitro
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curs as the last step of cypemycin biosynthesis. Accordingly, the
natural substrate of CypM would be a peptide containing the
Dhb residues and a C-terminal Avi-Cys moiety (Fig. 1).
We synthesized a series of short oligopeptides resembling the
N-terminal sequence of cypemycin, in which the Dhb residues
were replaced with Ala, Ser or Thr. As shown in Table 1, in the
presence of S-adenosylmethionine (SAM) these peptides (entries
1–5) were methylated by CypM (Table 1 and Supplementary
Fig. S1–S5). Like the reaction with native substrate in which mono
and di-methylated product (cypemycin) was observed (see Fig. S7
in [16]), mono- and di-methylated products were both identiﬁed in
most cases, reﬂecting the relatively inefﬁcient in vitro methylation
of these short oligopeptides as well as the native substrate. How-
ever, the tolerance of CypM to Thr- and Ser- containing peptideFig. 3. (A) Structure of Hala, Halb and their methylated derivatives. The amino group
similarly represented as in Fig. 2. (B) MS spectra of Hala and Halb modiﬁed by CypM.indicates the rather relaxed substrate speciﬁcity of the enzyme,
as the N-terminus as well as the overall scaffold of cypemycin is
highly hydrophobic (Fig. 1). Moreover, the methylation is not con-
ﬁned to N-terminal Ala. Peptides with N-terminal Gly, Ser, and Met
residues were also modiﬁed by CypM (Table 1, entries 6–8), albeit
with reduced efﬁciencies (Supplementary Fig. S6–S8). Collectively,
these results indicate that CypM has a relaxed substrate speciﬁcity
and can methylate a series of short oligopeptides that mimic the
N-terminal sequence of cypemycin.
The ability of PrmA to methylate not only the N-terminal a-
amino group but also the e-amino group of Lys led us to investigate
whether CypM can also methylate the e-amino group of Lys, which
could be useful in histone research. We synthesized several oligo-
peptides similar to peptide 1 (AAPAAPA) but with Lys replace-
ments in various positions (peptides 9–11). As shown in Table 1,s on which methylation occurred are highlighted by dashed boxes. Structures are
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nus (entries 9–10) were not modiﬁed by CypM, but a peptide with
a Lys at the C-terminus (entry 11) was methylated, with both di-
and tetra-methylated products detected in the reaction mixture
(Supplementary Fig. S11). Detailed MS–MS analysis clearly showed
that di-methylation occurred almost entirely on the e-amino group
of Lys instead of the N-terminus (Supplementary Fig. S12), suggest-
ing that the e-amino group of Lys might be preferred over the N-
terminal amino group provided it is not near the N-terminus. We
note that cypemycin does not contain any Lys residues.
Cypemycin and many a-N-methylated proteins contain Pro res-
idues within a few amino acids of the N-termini [4,8,16], which
might be important for enzyme recognition. Indeed, a peptide in
which Pro3 was replaced by Ala (entry 12) was not modiﬁed by
CypM. CypM also did not methylate a peptide with an N-terminal
APK motif (entry 13) that is the target of NRMT; CypM and NRMT
share no sequence similarity.
3.2. Methylation of other peptide antibiotics
We next interrogated whether CypM could methylate structur-
ally unrelated peptide antibiotics. Nisin (Fig. 2A) represents the
best studied member of the lantibiotic family and has been widely
used in the food industry because of its potent antimicrobial activ-Fig. 4. Unrooted tree of selected bacterial methyltransferases generated by Bayesian MCM
Substrates for each clade of enzymes are shown, and the red arrows indicate the methyity and unique mode of action [26,27]. There is interest in expand-
ing its use to clinical applications in both human and animal health
products [28]. As nisin possesses an unmodiﬁed Ile residue at the
N-terminus, the a-N-methylation of this residue may potentially
improve the stability and the pharmacological properties of the
molecule by preventing proteolytic degradation by aminopepti-
dases. Incubation of CypM with nisin resulted in addition of three
methyl groups (Fig. 2B). Detailed MS–MS analysis revealed that
one methylation occurred on the N-terminal Ile with the other
two methylations on Lys12 (Supplementary Fig. S15). The MIC va-
lue of the methylated nisin A against Lactococcus Lactis HP
(ATCC11602) and Bacillus subtillis 168 (ATCC6633) was determined
to be 1.0 lM and 4 lM, 8-fold and 4-fold higher than that of nisin
A, respectively, indicating that the methylated nisin is still a potent
antibiotic. CypM may thus serve a methylating tool for diversiﬁca-
tion of peptide natural products.
We also evaluated haloduracin as substrate for CypM. Halodur-
acin is a two-component lantibiotic containing two distinct
peptides halduracin a (Hala) and b (Halb) (Fig. 3A), which act
synergistically to exhibit potent antibiotic activity [29,30]. Hala
contains a Cys residue at its N-terminus, which links to Cys8 by
a disulﬁde bond and forms a macrocyclic system, and Halb
possesses an N-terminal methyllanthionine ring (Fig. 3A). Intrigu-
ingly, both Hala and Halb were methylated by CypM, and theC method. Support for the major clades is indicated by posterior probability values.
lation sites.
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both cases (Fig. 3B). MS–MS spectrometric analysis indicated that,
although both Hala and Halb contain Lys residues, methylation
occurred on the N-terminal amino group in both cases (Supple-
mentary Fig. S16–17). Given the considerable structural difference
between the native substrate of CypM (desmethyl-cypemycin)
and nisin and haloduracin, the catalytic promiscuity of CypM
demonstrated herein is surprising. The factors that determine
methylation of either a-N-amino or Lys e-amino groups in differ-
ent structural contexts, however, is currently unclear and requires
structural studies.
3.3. Evolution of bacterial a-N-methyltransferases
A search of CypM homologs in the National Center for Biotech-
nology Information (NCBI) sequence database revealed that except
for GrmM, involved in the biosynthesis of grisemycin (a cypemycin
structural variant), proteins with homology to CypM share only
modest sequence identities with CypM. These homologous
proteins include the a-N-methyltransferase PznL for plantazolicin
biosynthesis (Fig. 1), LmbJ and CcbJ that are involved in the
biosynthesis of lincomycin and celesticetin, respectively [31,32],
and several proteins that are designated as ubiquinone/menaquin-
one methylase UbiE [33]. However, most proteins with sequence
homology to CypM in the NCBI database are functionally
uncharacterized.
We used the Bayesian MCMC method to construct the phylo-
genetic inference of CypM and other bacterial methyltransferases
[34]. Several UbiE enzymes identiﬁed from the ubiquinone/men-
aquinone biosynthetic gene clusters of different genera and three
methyltransferases proposed to be involved in producing cype-
mycin-like natural products [16] were included in the analysis.
Several RsmE proteins that methylate the imide nitrogen N3 of
a unique uridine (U1489 for Escherichia coli) of 16S rRNAs
[35,36] were also included for comparative analysis. The
Bayesian MCMC tree shown in Fig. 4 clearly indicates that bacte-
rial a-N-methyltransferases did not evolve together, as CypM,
PnzL and PrmA fall into different clades with strong posterior
probability support. CypM and GrmM, LmbJ and CcbJ, and other
methyltransferases for putative cypemycin-like natural product
biosynthesis form a distinct clade. Given the close phylogenetic
relationship and sequence similarities of CypM with UbiE
enzymes, it is likely that CypM and other enzymes in the same
clade have evolved from ancient UbiE enzymes despite the latter
being C-methyltransferases [33]. PrmA [12,37,38] seems to have
a closer relationship with RsmE than with CypM, suggesting that
these two a-N-methyltransferases evolved from different ances-
tors. Although PznL is an a-N-methyltransferase involved in
ribosomal natural product biosynthesis like CypM, it is phyloge-
netically distant from CypM and falls into a distinct clade
(Fig. 4). The phylogenetic analysis demonstrates that a-N-meth-
yltransferases did not evolve based on the chemical reaction of
methylating N-terminal amino groups, but rather were acquired
through convergent evolution from diverse precursors with dif-
ferent functions. It has previously been suggested that some
plant O-methyltransferases might also have undergone conver-
gent evolutionary processes [39].
In conclusion, we demonstrate that CypM, an a-N-methyltrans-
ferase involved in cypemycin biosynthesis, has high catalytic ﬂexi-
bility and can act on a series of structurally distinct substrates,
including the lantibiotic nisin. Combined with the studies of NRMT
[8] andPrmA[12,37,38], it seems that catalytic promiscuity is a com-
mon property of a-N-methyltransferase enzymes, which appear to
have evolved by distinct pathways. The ﬂexibility of a-N-meth-
ytransferasesmayﬁndutility inmethylationof therapeutic peptides
that are metabolized by aminopeptidases.Acknowledgements
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